Literature DB >> 2458366

Extracellular matrix receptors, ECMRII and ECMRI, for collagen and fibronectin correspond to VLA-2 and VLA-3 in the VLA family of heterodimers.

Y Takada1, E A Wayner, W G Carter, M E Hemler.   

Abstract

The Very Late Activation Antigen (VLA) proteins are a family of five related heterodimers, which also are part of the integrin superfamily of cell adhesion molecules. Except for the identification of VLA-5 as a fibronectin receptor structure, the functions of the VLA proteins have remained unclarified. In this paper, immunoprecipitation experiments with both anti-alpha and anti-beta subunit antibodies showed that the previously identified cell adhesion receptor for collagen, extracellular matrix receptor II (ECMRII), is equivalent to VLA-2. At the same time a previously described multispecific cell adhesion receptor for collagen, fibronectin, and laminin (ECMRI) has been shown to be identical to VLA-3. Although the mAb 12F1 and P1H5 both recognized VLA-2 (ECMRII), they appeared to define distinct epitopes on the alpha 2 subunit. On the other hand, the mAb P1B5 and J143 recognized the alpha 3 subunit of VLA-3 (ECMRI) at or near the same site. Consistent with the collagen receptor functions of VLA-2 (ECMRII) and VLA-3 (ECMRI), anti-VLA beta antiserum blocked cell attachment to collagen.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2458366     DOI: 10.1002/jcb.240370406

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  66 in total

Review 1.  Physiological and pathological roles of alpha3beta1 integrin.

Authors:  Tsutomu Tsuji
Journal:  J Membr Biol       Date:  2004-08-01       Impact factor: 1.843

2.  Distinct mechanism of human neuroblastoma cell adhesion to fibronectin.

Authors:  T Yoshihara; S Ikushima; Y Shimizu; N Esumi; S Todo; M J Humphries; S Imashuku
Journal:  Clin Exp Metastasis       Date:  1991 Jul-Aug       Impact factor: 5.150

3.  Distinct determinants on collagen support alpha 2 beta 1 integrin-mediated platelet adhesion and platelet activation.

Authors:  S A Santoro; J J Walsh; W D Staatz; K J Baranski
Journal:  Cell Regul       Date:  1991-11

4.  Neutrophil bactericidal activity against Staphylococcus aureus adherent on biological surfaces. Surface-bound extracellular matrix proteins activate intracellular killing by oxygen-dependent and -independent mechanisms.

Authors:  M Hermann; M E Jaconi; C Dahlgren; F A Waldvogel; O Stendahl; D P Lew
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

5.  Human colon carcinoma cells use multiple receptors to adhere to laminin: involvement of alpha 6 beta 4 and alpha 2 beta 1 integrins.

Authors:  M M Lotz; C A Korzelius; A M Mercurio
Journal:  Cell Regul       Date:  1990-02

6.  The integrin VLA-2 binds echovirus 1 and extracellular matrix ligands by different mechanisms.

Authors:  J M Bergelson; B M Chan; R W Finberg; M E Hemler
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

7.  Widespread histologic distribution of the alpha 2 beta 1 integrin cell-surface collagen receptor.

Authors:  M M Zutter; S A Santoro
Journal:  Am J Pathol       Date:  1990-07       Impact factor: 4.307

8.  The human integrin VLA-2 is a collagen receptor on some cells and a collagen/laminin receptor on others.

Authors:  M J Elices; M E Hemler
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

9.  Localization of integrin receptors for fibronectin, collagen, and laminin in human skin. Variable expression in basal and squamous cell carcinomas.

Authors:  J Peltonen; H Larjava; S Jaakkola; H Gralnick; S K Akiyama; S S Yamada; K M Yamada; J Uitto
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

10.  Invasion by cultured human follicular thyroid cancer correlates with increased beta 1 integrins and production of proteases.

Authors:  M J Demeure; C H Damsky; F Elfman; P E Goretzki; M G Wong; O H Clark
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.